Physician practice in the discontinuation of statins among patients with advanced lung cancer

Journal of Palliative Care

Volumn 22, Issue 4, 2006, Pages 281-285

  Tanvetyanon, Tawee ^a   Choudhury, Abdul M ^b,c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b HINES VA HOSPITAL   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33846166732     PISSN: 08258597     EISSN: None     Source Type: Journal    
DOI: 10.1177/082585970602200405     Document Type: Article

References (21)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-1389.
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339(19): 1349-1357.
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 23-33.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333(20): 1301-1307.
5. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations. Lancet 2003; 361(9364): 1149-1158.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-2497.
7. Sandler AB, Gray R, Brahmer J, Dowlati A, Schiller JH, Perry MC, et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Proc ASCO 2005; 23: A4 [abstract].
8. Read WL, Tierney RM, Page NC, Costas I, Govindan R, Spitznagel EL, et al. Differential prognostic impact of comorbidity. J Clin Oncol 2004; 22(15): 3099-3103.
9. Ardizzoni A, Favaretto A, Boni L, Baldini E, Castiglioni F, Antonelli P, et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis. J Clin Oncol 2005; 23(3): 569-575.
10. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 2001;19(4):1064- 1070.
11. Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coebergh JW. Prevalence of comorbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998; 21(2): 105-113.
12. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004; 22(2): 315-321.
13. Christakis NA, Escarce JJ. Survival of Medicare patients after enrollment in hospice programs. N Engl J Med 1996; 335(3): 172-178.
14. Weeks JC, Cook EF, O'Day SJ, Peterson LM, Wenger N, Reding D, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 1998; 279(21): 1709-1714. Erratum in: JAMA 2000; 283(2): 203.
15. Kubler-Ross E, Wessler S, Avioli LV. On death and dying. JAMA 1972; 221(2): 174-179.
16. Gotto AM Jr. Safety and statin therapy: reconsidering the risks and benefits. Arch Intern Med. 2003; 163(6): 657-659.
17. Hay JW, Yu WM, Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics 1999; 15(1): 47-74.
18. Lutz S, Norrell R, Bertucio C, Kachnic L, Johnson C, Arthur D, et al. Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospital. J Palliat Med 2001; 4(2): 157-165.
19. Sleijfer S, van der Gaast A, Planting AS, Stoter G, Verweij J. The potential of statins as part of anti-cancer treatment. Eur J Cancer 2005; 41(4): 516-522.
20. Khanzada UK, Pardo OE, Meier C, Downward J, Seckl MJ, Arcaro A. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene 2006; 25(6): 877-887.
21. Williams JP, Hernady E, Johnston CJ, Reed CM, Fenton B, Okunieff P, et al. Effect of administration of lovastatin on the development of late pulmonary effects after whole-lung irradiation in a murine model. Radiat Res 2004; 161(5): 560-567.